Roth Capital Starts Actinium Pharma (ATNM) at Buy, PT $5

Roth Capital initiated coverage on Actinium Pharma (NYSE: ATNM) with a Buy rating and a price target of $5.00.

For an analyst ratings summary and ratings history on Actinium Pharma click here. For more ratings news on Actinium Pharma click here.

Shares of Actinium Pharma closed at $1.66 yesterday.

You May Also Be Interested In

• Actinium Pharma (ATNM) Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML
• JMP Securities Starts The RMR Group Inc. (RMR) at Market Perform, 'Pure-Pay'
• Northcoast Research Starts Deluxe Corp (DLX) at Buy